Financing ·
Lucid Diagnostics raises $15M via Series C Preferred Stock sale to accredited investors
PAVMPAVmed Inc.
Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed a private placement on October 21, 2026, selling 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share. The transaction generated gross proceeds of $15.0 million for the subsidiary. Investors received registration rights to facilitate the resale of common stock issuable upon conversion of the preferred shares. PAVmed Inc. operates in the medical device industry.